More employers are planning to drop coverage of GLP-1 drugs for weight loss next year as increasing numbers of people take the medications

A new analysis found the average drug shortage in 2025 had lasted 5.3 years, exceeding the 4.3 years seen in 2024

The number of prescription drug shortages in the U.S. fell by 23% last year, but a new analysis found other troubling signs about medicines in short supply.

Lilly disclosed new data that provide more details on the safety and tolerability of its next-generation obesity drug retatrutide

From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.

The Supreme Court unanimously ruled that Hikma Pharmaceutical did not infringe patents held by Amarin in a decision with implications for lawsuits over so-called skinny labels.

For pancreatic cancer patients, the surge in interest for an exciting new drug is leaving them fearful about when they might get the treatment or if there will be enough…

Eli Lilly is halving its originally planned investment in the production of weight loss syringes in Germany in response to a cost-cutting law

Taking weight loss drugs for at least three years could prevent thousands of knee replacements a year, a new study found

Lilly gave hospitals participating in a federal drug discount program five days to submit claims data or it will stop the price breaks

Eli Lilly has told more than 1,000 hospitals participating in the 340B drug discount program to submit claims data over the next five days — or lose price breaks.

Detailed study data for a pancreatic cancer treatment from Revolution Medicines confirmed it increased overall survival, from 13.2 months to 6.7 months

Pharma updates from the Pharmalot campus via the Pharmalittle newsletter

From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.

In this morning's Pharmalittle roundup, we're reading about a hepatitis B drug, CVS returns Lilly obesity drug to formularies, and more.

The FDA extended the decision deadline for an experimental breast cancer pill from AstraZeneca after an advisory panel voted against the drug

Eli Lilly reported that a high dose of its gene-editing therapy reduced cholesterol levels by 62% in participants in a Phase 1 clinical trial

Biogen and Denali said their experimental Parkinson’s therapy failed to slow the degenerative brain disorder in a randomized trial

How a pharma company is soliciting research that can be used to blunt pharma proposed reforms in Washington.

For Wall Street, the political risk of investing in drug companies has been demoted in comparison to other concerns

Virginia's governor vetoed a closely watched effort to create an advisory panel to lower prescription drug costs.

Most Canadian medical societies lack comprehensive policies governing conflicts of interest, and many policies are generally fragmented and narrow in scope, according to a new analysis.

Nine states have been pursuing the idea of prescription drug affordability boards. Maryland's board just set limits on the price of Ozempic.

The question of whether to partner with Chinese firms — or see them as rivals — is tearing biotech apart, pitting peers and partners against one another

A pair of advocacy groups is threatening legal action unless the U.K. government revokes regulations at the heart of a new pharma trade agreement with the U.S.

Takeda Pharmaceuticals agreed to pay $13.6 million to settle allegations that it paid kickbacks to doctors to prescribe an antidepressant.

From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.

In today's Pharmalittle roundup: U.S. pressuring Germany on drug prices, FDA upheaval and biotech clinical trials, and much more.

The CDC intends to transfer more than 160 macaques to Born Free USA, a nonprofit that runs a large primate sanctuary in Texas, as the agency seeks to phase out…

Biogen reported mixed results from a mid-stage clinical trial investigating a treatment for Alzheimer’s disease that targets the protein tau